C

Cardiff Oncology
D

CRDF

3.34000
USD
-0.40
(-10.70%)
قبل الجلسة
حجم التداول
483
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
222,196,352
أصول ذات صلة
C
CELH
0.470
(1.00%)
47.435 USD
E
EXPI
0.030
(0.27%)
11.210 USD
M
MOGO
-0.09500
(-5.54%)
1.62000 USD
S
SENS
-0.03660
(-6.82%)
0.50020 USD
S
SNDL
-0.04500
(-3.01%)
1.45000 USD
V
VRA
0.03000
(1.34%)
2.27000 USD
I
IQST
0.04500
(0.49%)
9.17500 USD
المزيد
الأخبار المقالات

العنوان: Cardiff Oncology

القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.